Navigation Links
cusa selector™ Ultrasonic Aspirator

Productscusa selector™ Ultrasonic Aspirator
Company Integra LifeSciences Corporation
Item cusa selector™ Ultrasonic Aspirator
Features 
  • Quick and simple to set up
  • Easy to read digital display
  • Compact design with small footprint
  • Automatic pinch valve to protect tissues during handpiece withdrawal
  • Smooth running peristaltic pump requiring no extra clamp for irrigation control
  • Linear foot pedal for surgeon control
  • Available as an MRI version compatible with the current leading model from GE systems
Description Selector has everything you expect from the long-established Selector Ultrasonic Aspirator along with the advantage of integrated circuitry and the small, ergonomic 24kHz microsurgical handpiece.

Unlike other surgical techniques, ultrasonic surgery selectively dissects soft tissues leaving fibrous tissues such as nerves and blood vessels relatively unaffected. It therefore facilitates the ablation of unwanted tissue adjacent or attached to vital structures.

Info Integra LifeSciences Corporation
Customer Service: (800) 654-2873
Web site: http://www.integra-ls.com/

Related medicine products :

1. Ultrasonic Pachymeter UP-1000
2. Compact Ultrasonic Phacoemulsification System
3. Dissectron Ultrasonic Aspirator
4. CUSA Excel Ultrasonic Surgical Aspirator
5. OSCAR Ultrasonic Bone Cement Remover
6. Ultrasonic Pachometer
7. The Ultrasonic BioMicroscope (UBM P40)
8. The P45 Ultrasonic Workstation
9. UD-6000 Ultrasonic A/B Scanner and Biometer
10. UD-1000 Ultrasonic B-Scanner
11. DGH Pachette 3 Ultrasonic Pachymeter
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the quantitative determination of total glucose in serum.
Glucose reagent is used for the quantitative determination of glucose in human serum.
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent.
Medicine Products:
(Date:11/21/2008)...for preterm labor , , FRIDAY, Nov. 21 (H...e switch that activates the uterine muscles for co...ad to therapies for preterm labor. , The molec...the surface of these uterine muscle cells, keeping...But researchers from Dartmouth Medical School in N...
(Date:11/21/2008)... State University College of Medicine research tea... new layer of regulation in the cell division cycl...the way cancer begins. , Wang, an assistant prof...icine, said the findings will lead to an improved ...esign of new drugs that kill cancer cells by inhib...
(Date:11/21/2008)...re-FirstCall/ -- Heska Corporation,(Nasdaq: HSK...k Society of,Security Analysts, 12th Annual Biote... 2008 at 1177 Avenue of the Americas, 2nd Floor in...egin at 9:35 a.m. Eastern Time (7:35 a.m.,Mountai... for two weeks,following the presentation through...
(Date:11/21/2008)...out future antibiotic resistance from widespread u...) -- People with moderate to severe chronic obstru...ce the frequency of exacerbations through a regula...ays. , The study, published in the first issue...ory and Critical Care Medicine , found that twice-...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2
...ed from patients who are in for these tests. Resea...t present which will help spare some couples the c...e Werlin, M.D., and researchers from the Genesis N...olved in a study looking at the benefits of preimp...
... into energy-producing muscle fibres – mocking the...ard Medical School discovered a protein in muscle ...rsity of Texas, they reveal that the protein has t...There are two types of muscle fibre. Type II is th...
...ry did not improve, attention or concentration in ...l extract much prized for many years for its effec...gested it may be helpful in improving memory //in ...ko can increase mental sharpness in those who are ...
...ioxidant treatment improves circulation and reduce... Peripheral artery disease is a narrowing of the a...cts an estimated 5 million to 10 million people in...have no symptoms, one of the major signs of the co...
Other Medicine News:
(Date:11/19/2008)... -- Biotech scientists increasingly are applying g...ter understand the effects of novel drug candidate...Engineering & Biotechnology News ( GEN ). The...compound,s mechanism of action and eventually deve...g to the November 15 issue of GEN . ( http://www....
(Date:11/18/2008)...l/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialty ... Company,and Sosei Group Corporation ("Sosei"; T...biopharmaceutical company, today announce that Neu...nical efficacy data for NSL-043/SD118.,This inves...thic pain and has,successfully completed Phase I ...
(Date:11/18/2008)...wswire/ -- Forty-two leading U. S. scientists and ...to consider cutting-edge innovations that may defe...om outbreaks of dangerous zoonotic diseases, the F... innovations: , , , , A "Doc in...ts highly contagious and dangerous zoonotic diseas...
(Date:11/13/2008)...FirstCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a le...ium,diagnostics, medical imaging systems and surgi...eeds of women, today announced the results of the,... Cervista HPV high-risk,test is currently under re...launched in the European Union (EU) early in 2009....
Breaking Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 1Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 2Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 3Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4322 4Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections 4317 1Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections 4317 2Abbott Announces Positive One Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 599 1Abbott Announces Positive One Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 599 2Abbott Announces Positive One Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 599 3drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 1drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 2drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 3drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 4drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 5drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 6drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 7drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 8drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 9drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 10drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 11drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 12drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 13drugstore com inc Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007 4311 14
...NEW YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE...d that data from preclinical,studies of INNO-406, ...r for Gleevec-resistant or treatment-intolerant ch...he American Association,for Cancer Research Annual...7 at the Los Angeles Convention Center in Los Ange...
... BRANFORD, Conn., April 12, 2007 /PRNewswire-First...new preclinical data on,belinostat (PXD101), a his...ed for the treatment of cancer, and velafermin, a ...evere oral mucositis,will be presented at the upc...CR) 2007 Annual Meeting in Los Angeles, CA, April,...
Other Medicine Technology:Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4